Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Luhu Shan"'
Autor:
Xin Chai, Huiyong Sun, Wenfang Zhou, Changwei Chen, Luhu Shan, Yuhui Yang, Junzhao He, Jinping Pang, Liu Yang, Xinyue Wang, Sunliang Cui, Yaqin Fu, Xiaohong Xu, Lei Xu, Xiaojun Yao, Dan Li, Tingjun Hou
Publikováno v:
Journal of Medicinal Chemistry. 65:2507-2521
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc26bb38c9f8641ef0366de40eafadde
https://doi.org/10.1021/acs.jmedchem.1c01938
https://doi.org/10.1021/acs.jmedchem.1c01938
Autor:
Qing Tang, Mojie Duan, Luhu Shan, Xuwen Wang, Yi-Xuan Lei, Weitao Fu, Xin Chai, Jianing Liao, Zhou Gong, Xiaohong Xu, Tingjun Hou, Dan Li, Minkui Zhang, Chun Tang, Jinping Pang, Rong Sheng
Publikováno v:
Journal of Medicinal Chemistry. 64:17221-17238
Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist 92 targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), 92 d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11ea50e6057d00771c5aa8aa56b94b5a
https://doi.org/10.1021/acs.jmedchem.1c01287
https://doi.org/10.1021/acs.jmedchem.1c01287
Autor:
Xueping Hu, Tingjun Hou, Xiaohong Xu, Lei Xu, Dan Li, Li Xiao, Ying Shao, Yunxia Wang, Dan-yan Zhu, Jinping Pang, Chao Shen, Wenfang Zhou, Xin Chai, Feng Zhu, Luhu Shan
Publikováno v:
Acta Pharmacol Sin
Background and Purpose: Androgen receptor (AR), a ligand-activated transcription factor, is a master regulator in the development and progress of prostate cancer (PCa). A major challenge for the clinically used AR antagonists is the rapid emergence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a06034a5211db44638ab7323211dc418
https://doi.org/10.1038/s41401-021-00632-5
https://doi.org/10.1038/s41401-021-00632-5
Autor:
Xin, Chai, Huiyong, Sun, Wenfang, Zhou, Changwei, Chen, Luhu, Shan, Yuhui, Yang, Junzhao, He, Jinping, Pang, Liu, Yang, Xinyue, Wang, Sunliang, Cui, Yaqin, Fu, Xiaohong, Xu, Lei, Xu, Xiaojun, Yao, Dan, Li, Tingjun, Hou
Publikováno v:
Journal of medicinal chemistry. 65(3)
Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting sit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1999233bc8b4e0b14e1d516afa089cab
https://pubmed.ncbi.nlm.nih.gov/35077161
https://pubmed.ncbi.nlm.nih.gov/35077161